IL308063A - Expanded dosage regimens for integrin inhibitors - Google Patents
Expanded dosage regimens for integrin inhibitorsInfo
- Publication number
- IL308063A IL308063A IL308063A IL30806323A IL308063A IL 308063 A IL308063 A IL 308063A IL 308063 A IL308063 A IL 308063A IL 30806323 A IL30806323 A IL 30806323A IL 308063 A IL308063 A IL 308063A
- Authority
- IL
- Israel
- Prior art keywords
- expanded
- dosing regimens
- integrin inhibitors
- integrin
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 102000006495 integrins Human genes 0.000 title 1
- 108010044426 integrins Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182757P | 2021-04-30 | 2021-04-30 | |
| PCT/US2022/072013 WO2022232838A1 (en) | 2021-04-30 | 2022-04-29 | Expanded dosage regimens for integrin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308063A true IL308063A (en) | 2023-12-01 |
Family
ID=83848780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308063A IL308063A (en) | 2021-04-30 | 2022-04-29 | Expanded dosage regimens for integrin inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230028658A1 (enExample) |
| EP (1) | EP4329755A4 (enExample) |
| JP (1) | JP2024517765A (enExample) |
| KR (1) | KR20240024060A (enExample) |
| CN (1) | CN117615760A (enExample) |
| AU (1) | AU2022265730A1 (enExample) |
| CA (1) | CA3173787A1 (enExample) |
| CL (1) | CL2023003219A1 (enExample) |
| CO (1) | CO2023016295A2 (enExample) |
| CR (1) | CR20230553A (enExample) |
| IL (1) | IL308063A (enExample) |
| MX (1) | MX2023012794A (enExample) |
| TW (1) | TW202308637A (enExample) |
| WO (1) | WO2022232838A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| EP3952902A4 (en) | 2019-04-08 | 2022-12-21 | Pliant Therapeutics, Inc. | DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS |
| TW202235417A (zh) | 2020-11-19 | 2022-09-16 | 美商普萊恩醫療公司 | 整合素抑制劑及其用途 |
| US20250197393A1 (en) | 2023-12-14 | 2025-06-19 | Pliant Therapeutics, Inc. | Integrin inhibitor and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110167934B (zh) * | 2016-11-08 | 2022-06-10 | 百时美施贵宝公司 | 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物 |
| JP2021507884A (ja) * | 2017-12-15 | 2021-02-25 | アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 投与レジメンならびに関連組成物および方法 |
| CU24684B1 (es) * | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| EP3952902A4 (en) * | 2019-04-08 | 2022-12-21 | Pliant Therapeutics, Inc. | DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS |
| KR20230049584A (ko) * | 2020-05-07 | 2023-04-13 | 플라이언트 테라퓨틱스, 인크. | 아미노산 화합물을 사용한 호흡기 질환의 치료 |
| JP2024539645A (ja) * | 2021-10-14 | 2024-10-29 | プライアント・セラピューティクス・インコーポレイテッド | インテグリン阻害剤及び他の薬剤と組み合わせたその使用 |
-
2022
- 2022-04-29 US US17/733,488 patent/US20230028658A1/en not_active Abandoned
- 2022-04-29 CR CR20230553A patent/CR20230553A/es unknown
- 2022-04-29 AU AU2022265730A patent/AU2022265730A1/en not_active Abandoned
- 2022-04-29 MX MX2023012794A patent/MX2023012794A/es unknown
- 2022-04-29 TW TW111116506A patent/TW202308637A/zh unknown
- 2022-04-29 WO PCT/US2022/072013 patent/WO2022232838A1/en not_active Ceased
- 2022-04-29 IL IL308063A patent/IL308063A/en unknown
- 2022-04-29 CN CN202280046288.9A patent/CN117615760A/zh active Pending
- 2022-04-29 CA CA3173787A patent/CA3173787A1/en active Pending
- 2022-04-29 JP JP2023566804A patent/JP2024517765A/ja active Pending
- 2022-04-29 KR KR1020237041401A patent/KR20240024060A/ko not_active Withdrawn
- 2022-04-29 EP EP22796995.3A patent/EP4329755A4/en not_active Withdrawn
-
2023
- 2023-10-26 CL CL2023003219A patent/CL2023003219A1/es unknown
- 2023-11-29 CO CONC2023/0016295A patent/CO2023016295A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20230553A (es) | 2024-04-01 |
| AU2022265730A1 (en) | 2023-11-16 |
| EP4329755A4 (en) | 2025-03-19 |
| TW202308637A (zh) | 2023-03-01 |
| MX2023012794A (es) | 2023-12-15 |
| KR20240024060A (ko) | 2024-02-23 |
| CN117615760A (zh) | 2024-02-27 |
| WO2022232838A1 (en) | 2022-11-03 |
| CA3173787A1 (en) | 2022-11-03 |
| JP2024517765A (ja) | 2024-04-23 |
| EP4329755A1 (en) | 2024-03-06 |
| US20230028658A1 (en) | 2023-01-26 |
| CO2023016295A2 (es) | 2023-12-11 |
| CL2023003219A1 (es) | 2024-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280782A (en) | Inhibiting αv β6 integrin | |
| EP4216951A4 (en) | KRAS G12D INHIBITORS | |
| EP4262803A4 (en) | Tetrahydropyridopyrimidine pan-kras inhibitors | |
| EP4007756C0 (en) | KIF18A INHIBITORS | |
| IL268947A (en) | Inhibitors of (alpha-v)(beta-6) integrin | |
| PL3578547T3 (pl) | Pochodne sulfonylomocznika i związki pokrewne oraz ich zastosowanie | |
| IL286145A (en) | Systems and methods for drug-agnostic patient-specific dosing regimens | |
| EP4140573A4 (en) | AEROSOL GENERATING DEVICE | |
| DK3844162T3 (da) | Hæmmere af alfa-v-beta6-integrin | |
| EP4313967C0 (en) | CHD Inhibitor | |
| EP4247372A4 (en) | PLASMA KALLICREIN INHIBITORS | |
| EP4171538A4 (en) | Selective histone deacetylase 6 inhibitors | |
| EP4177180A4 (en) | CONTAINER | |
| EP4452967A4 (en) | SARS-CoV-2 INHIBITORS | |
| EP3976797A4 (en) | ANTI-CRISPR INHIBITORS | |
| EP4226919A4 (en) | FERROPTOSIS INHIBITOR | |
| EP4210694A4 (en) | PLASMA KALLICREIN INHIBITORS | |
| EP4178620A4 (en) | PLASMA KALLICREIN INHIBITORS | |
| EP4087845A4 (en) | BTK INHIBITORS | |
| EP4101781A4 (en) | Container | |
| EP4405334C0 (en) | Sortilin inhibitors | |
| EP4347418C0 (en) | CONTAINER | |
| JP1748149S (ja) | コンテナー | |
| IL280515A (en) | Dosing regimens for elagolix | |
| EP4132857C0 (en) | WRAP CONTAINER |